Russia’s top pharmaceutical companies may suspend implementation of projects which involve the expansion of their production capacities, due to existing sanctions regimes and ongoing geopolitical tensions with Western countries, according to recent statements from the heads of some leading companies, reports The Pharma Letter’s local correspondent. 4 September 2018
US President Donald Trump’s recently initiated trade war with China has divided opinion between those who see it as a potentially industry-damaging misstep, and those who view the Chinese state as an aggressive opponent increasingly willing to rig the global trading system in its favor. 4 September 2018
A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level. 4 September 2018
London-listed Arix Bioscience has announced a change to its executive team which will see current chief executive Joe Anderson moved to the role of chief investment officer. 4 September 2018
Switzerland-based Tillotts Pharma, part of the Japanese Zeria Group, has announced that Karima Boubekeur is joining the company to take on the newly-created role of global head of innovation. 3 September 2018
Before joining Boston University to study biomedical engineering and chemistry, Mass Innovation Labs founder Amrit Chaudhuri was the youngest paid researcher at the MIT-affiliated Whitehead Institute for Biomedical Research, at age 15. 3 September 2018
Holding sway in the Indian market, multinational pharmaceutical companies are looking to increase their market share in the $33 billion domestic industry. Taking note of the new opportunities, many global majors have begun to make meaningful investments in the country, reports The Pharma Letter’s India correspondent. 1 September 2018
In an Expert View piece, Elisabethann Wright and Jane Summerfield, from law firm Hogan Lovells, look at some useful points to come out of the UK government regarding the implications of a ‘hard Brexit’. 31 August 2018
EMD Serono, the biopharmaceutical business of Merck KGaA in the USA and Canada, today announced that Rehan Verjee has been appointed president of EMD Serono and global head of innovative medicine franchises of Merck. 31 August 2018
Indianapolis, USA-based Eli Lilly has announced that Anne White is to become president of Lilly Oncology and senior vice president of Lilly, effective September 1, 2018. 31 August 2018
US pharma major Bristol-Myers Squibb yesterday announced that Christopher Boerner has been appointed executive vice president and chief commercial officer, effective immediately. 29 August 2018
Russia plans to offer a special ‘green corridor’ for pharmaceutical companies from Japan that are interested in establishing production within the country, according to recent statements of Russia’s Vice Prime Minister Olga Golodets, one of the people, responsible for the development of pharmaceutical industry in the Russian government, reports The Pharma Letter’s local correspondent. 24 August 2018
Russia’s leading drugmaker Biocad will start the production of drugs against cancer and autoimmune diseases as of 2019, according to recent statements by the authorities of St Petersburg. 24 August 2018
In light of a report on the 10 most important medicines over the life of the UK's National Health Service (NHS), the Association of the British Pharmaceutical Industry's (ABPI) deputy chief scientific officer, Sheuli Porkess, outlines how pharma's process of taking a substance from molecule to medicine requires persistence. 24 August 2018
Vertex Pharmaceuticals today announced that Ludovic Fenaux has been appointed senior vice president, international commercial operations with responsibility for commercial activities outside of the USA and Canada, which includes overseeing offices and operations across Europe, Australia and Latin America. 23 August 2018
Making patients the owners of and beneficiaries from their own data will be key to making blockchain technology deliver for healthcare as a whole, according to the theory behind a network that could convert siloed information into a connected driver of better research and outcomes. 22 August 2018
Rare diseases specialist Swedish Orphan Biovitrum has appointed Anne Marie de Jonge Schuermans as head of its new Technical Operations organization, bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety operations. 22 August 2018
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024